727 articles|Clear filters
General AML, FLT3
1st NCRI AML academy meeting | Does current evidence support FLT3 maintenance therapy?
1st NCRI AML academy meeting | An overview of the UK AML trial landscape
Gilteritinib receives positive recommendation from EMA CHMP for the treatment of FLT3-mutated AML
Emily Smith , Sep 23, 2019 , Expert Opinion
Nivolumab as an addition to frontline therapy of AML in younger patients
Samantha Larkin , Sep 19, 2019